The results of this analyses can serve as a basis for further clinical studies formulating novel treatment strategies for ALK-p ALK inhibitor-naïve advanced NSCLC with CNS metastases or acquired resistance mutations. Here, ALK is linked to non-small cell lung carcinoma.